| CTSH |
Report |
Revenue |
IN-LINE |
pred ~$5.50B vs. cons $5.49B |
MEDIUM |
| CTSH |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$1.40 vs. cons $1.38 |
MEDIUM |
| CTSH |
Report |
Q2 bookings growth |
MISS |
pred ~12% y/y vs. cons 15% y/y |
LOW |
| CTSH |
Guide |
FY26 constant-currency revenue growth |
UNCHANGED |
guide ~5.25% midpoint vs. cons 5.30% (FY26) |
MEDIUM |
| CTSH |
Guide |
FY26 adjusted operating margin |
UNCHANGED |
guide ~16.10% midpoint vs. cons 16.10% (FY26) |
MEDIUM |
| CTSH |
Guide |
FY26 adjusted diluted EPS |
UNCHANGED |
guide ~$5.70 midpoint vs. cons $5.70 (FY26) |
MEDIUM |
| CTSH |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.5% |
— |
MEDIUM |
| CTSH |
Return |
5-day cumulative residual |
-5.0% (FOLLOW-THROUGH) |
A ~$1.40 EPS result versus $1.38 consensus is offset by predicted bookings growth of ~12% versus ~15% consensus and an FY26 CC-growth midpoint of ~5.25% versus ~5.30% consensus; unchanged out-period math leaves limited support for revisions. |
MEDIUM |